BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27016391)

  • 1. Cell subpopulation deconvolution reveals breast cancer heterogeneity based on DNA methylation signature.
    Wen Y; Wei Y; Zhang S; Li S; Liu H; Wang F; Zhao Y; Zhang D; Zhang Y
    Brief Bioinform; 2017 May; 18(3):426-440. PubMed ID: 27016391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles.
    Campoy EM; Branham MT; Mayorga LS; Roqué M
    BMC Cancer; 2019 Apr; 19(1):328. PubMed ID: 30953488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic control of phospholipase A2 receptor expression in mammary cancer cells.
    Menschikowski M; Hagelgans A; Nacke B; Jandeck C; Sukocheva O; Siegert G
    BMC Cancer; 2015 Dec; 15():971. PubMed ID: 26672991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential methylation hybridization profiling identifies involvement of STAT1-mediated pathways in breast cancer.
    Kim JH; Kang HS; Kim TW; Kim SJ
    Int J Oncol; 2011 Oct; 39(4):955-63. PubMed ID: 21674123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
    Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
    Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the breast cancer methylome using formalin-fixed paraffin-embedded tumour.
    Wong EM; Joo JE; McLean CA; Baglietto L; English DR; Severi G; Wu HC; Terry MB; Hopper JL; Milne RL; Giles GG; Southey MC
    Breast Cancer Res Treat; 2016 Nov; 160(1):173-180. PubMed ID: 27604360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining the effect of DNA methylation on gene expression in cancer cells.
    Lee CJ; Evans J; Kim K; Chae H; Kim S
    Methods Mol Biol; 2014; 1101():161-78. PubMed ID: 24233782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin.
    Lee SE; Kim SJ; Yoon HJ; Yu SY; Yang H; Jeong SI; Hwang SY; Park CS; Park YS
    J Pineal Res; 2013 Jan; 54(1):80-8. PubMed ID: 22856590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homeobox protein MSX1 inhibits the growth and metastasis of breast cancer cells and is frequently silenced by promoter methylation.
    Yue Y; Yuan Y; Li L; Fan J; Li C; Peng W; Ren G
    Int J Mol Med; 2018 May; 41(5):2986-2996. PubMed ID: 29436596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.
    To SQ; Takagi K; Miki Y; Suzuki K; Abe E; Yang Y; Sasano H; Simpson ER; Knower KC; Clyne CD
    J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):331-8. PubMed ID: 22929011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clofarabine, a novel adenosine analogue, reactivates DNA methylation-silenced tumour suppressor genes and inhibits cell growth in breast cancer cells.
    Lubecka-Pietruszewska K; Kaufman-Szymczyk A; Stefanska B; Cebula-Obrzut B; Smolewski P; Fabianowska-Majewska K
    Eur J Pharmacol; 2014 Jan; 723():276-87. PubMed ID: 24296317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
    Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation mediated silencing of microRNA-874 is a promising diagnosis and prognostic marker in breast cancer.
    Zhang L; Yan DL; Yang F; Wang DD; Chen X; Wu JZ; Tang JH; Xia WJ
    Oncotarget; 2017 Jul; 8(28):45496-45505. PubMed ID: 28525377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes.
    Li Y; Li S; Chen J; Shao T; Jiang C; Wang Y; Chen H; Xu J; Li X
    Hum Mol Genet; 2014 Oct; 23(20):5378-93. PubMed ID: 24871326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour.
    Huang KT; Mikeska T; Li J; Takano EA; Millar EK; Graham PH; Boyle SE; Campbell IG; Speed TP; Dobrovic A; Fox SB
    BMC Cancer; 2015 Oct; 15():669. PubMed ID: 26452468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer].
    Noetzel E; Veeck J; Horn F; Hartmann A; Knüchel R; Dahl E
    Pathologe; 2008 Nov; 29 Suppl 2():319-27. PubMed ID: 18807039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic values of GHSR DNA methylation pattern in breast cancer.
    Botla SK; Gholami AM; Malekpour M; Moskalev EA; Fallah M; Jandaghi P; Aghajani A; Bondar IS; Omranipour R; Malekpour F; Mohajeri A; Babadi AJ; Sahin Ö; Bubnov VV; Najmabadi H; Hoheisel JD; Riazalhosseini Y
    Breast Cancer Res Treat; 2012 Oct; 135(3):705-13. PubMed ID: 22899222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer.
    Kang S; Kim B; Park SB; Jeong G; Kang HS; Liu R; Kim SJ
    Int J Oncol; 2013 Nov; 43(5):1659-65. PubMed ID: 24026393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.